I am a
Home I AM A Search Login

Papers of the Week


Curr Top Microbiol Immunol


Small Molecule Inhibitors Targeting Chikungunya Virus.


Haese N, Powers J, Streblow DN
Curr Top Microbiol Immunol. 2022; 435:107-139.
PMID: 31974761.


Chikungunya virus (CHIKV) infection in humans is rarely fatal but is often associated with chronic joint and muscle pain. Chronic CHIKV disease is highly debilitating and is associated with viral persistence. To date, there are no approved vaccines or therapeutics to prevent or treat CHIKV infections once they are established. Current palliative treatments aim to reduce joint inflammation and pain associated with acute and chronic CHIKV disease. Development of novel therapeutics that reduces viral loads should positively impact virus inflammatory disease and improve patient outcomes following CHIKV infection. Therapies that target multiple aspects of CHIKV replication cycle should be developed since the virus is capable of rapidly mutating around any single therapeutic. This review summarizes the current status of small molecule inhibitor development against CHIKV.